This is the authors' abstract. We don't add key points for this paper.
Somatic mutations in genes encoding isocitrate dehydrogenase (IDH) enzymes are found in approximately 20% of acute myeloid leukemia (AML) and are more common in patients with advanced age, intermediate risk-AML or NPM1 mutations [ 1 ]. They involve 3 mutational hotspots within the IDH enzymatic active sites, resulting in single amino acid substitutions at codon R132 of IDH1 ( IDH1 R132 ) and codons R140 and R172 of IDH2 ( IDH2 R140 and IDH2 R172 ). The prognostic significance of IDH1/2 mutations remains debated in the literature [ 2 , 3 , 4 , 5 , 6 ], and it remains unclear whether these mutations can be used as markers for measurable residual disease (MRD) monitoring [ 7 , 8 , 9 ].
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Dantec et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: